TherapeuticsMD (TXMD) Profit After Tax (2010 - 2026)

TherapeuticsMD (TXMD) has reported Profit After Tax for 17 consecutive years, with $164000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 70.24% year-over-year to $164000.0; the trailing twelve-month figure through Jun 2026 stood at -$292000.0 (up 50.51% YoY), and the FY2025 full-year result was -$653000.0, up 71.76% from the prior year.
• Profit After Tax improved to $164000.0 in Q2 2026 per TXMD's latest filing, from $95000.0 in the prior quarter.
• Across five years, Profit After Tax topped out at $159.4 million in Q4 2022 and bottomed at -$49.0 million in Q1 2022.
• Historically, Profit After Tax has averaged $10.0 million across 5 years, with a median of -$678000.0 in 2025.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax surged 470.99% in 2022, then sank 680.99% in 2025.
• Over 5 years, Profit After Tax stood at $159.4 million in 2022, then tumbled by 100.55% to -$883000.0 in 2023, then jumped by 113.7% to $121000.0 in 2024, then tumbled by 680.99% to -$703000.0 in 2025, then surged by 123.33% to $164000.0 in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $164000.0, $95000.0, and -$703000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.